Role of chemotherapy in pediatric nonrhabdomyosarcoma soft-tissue sarcomas

Expert Review of Anticancer Therapy

Volumn 8, Issue 6, 2008, Pages 929-938

  Ferrari, Andrea ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Adjuvant chemotherapy; Adult type soft tissue sarcomas of childhood; Histology driven therapy; Neoadjuvant chemotherapy; Nonrhabdomyosarcoma soft tissue sarcomas; Patient stratification; Prognostic variables; Synovial sarcoma; Targeted therapy

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MELPHALAN; TAXANE DERIVATIVE; TRABECTEDIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN INHIBITOR; VINCRISTINE;

ANGIOSARCOMA; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL TRIAL; DERMATOFIBROSARCOMA PROTUBERANS; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; EWING SARCOMA; EXTERNAL BEAM RADIOTHERAPY; FIBROSARCOMA; HEMANGIOENDOTHELIOMA; HUMAN; HYPERTHERMIC THERAPY; LEIOMYOSARCOMA; LOW DRUG DOSE; MULTIMODALITY CANCER THERAPY; MYXOSARCOMA; PATIENT SELECTION; PROGNOSIS; REVIEW; RISK ASSESSMENT; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; THERAPY DELAY; TREATMENT OUTCOME; TUMOR VOLUME; ADULT; CHILD; DRUG DELIVERY SYSTEM; DRUG RESISTANCE; SARCOMA; SOFT TISSUE TUMOR;

ADULT; ANTINEOPLASTIC AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; PATIENT SELECTION; PROGNOSIS; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 47249152832     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.6.929     Document Type: Review

References (71)

1. Okcu MF, Hicks J, Merchant TE et al. Nonrhabdomyosarcomatous soft tissue sarcomas, In: Principles and Practice of Pediatric Oncology (5th edition). Pizzo PA, Poplack DC (Eds). Lippincott, Williams & Wilkins, PA, USA, 1033-1073 (2006).
2. Raney B, Parham D, Sommelet-Olive D et al. Summary of the International Symposium on childhood non-rhabdomyosarcoma soft-tissue sarcomas, Padua, Italy, 1994. Med. Pediatr. Oncol. 26, 425-430 (1996).
3. Rao BN. Nonrhabdomyosarcoma in children: prognostic factors influencing survival. Semin. Surg. Oncol. 9, 524-531 (1993).
4. McGrory JE, Pritchard DJ, Arndt CA et al. Nonrhabdomyosarcoma soft tissue sarcomas in children: the Mayo Clinic experience. Clin. Orthop. 374, 247-258 (2000).
5. Spunt SL, Poquette CA, Hurt YS et al. Prognostic factors for children and adolscents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St Jude Children's Research Hospital. J. Clin. Oncol. 17, 3697-3705 (1999).
6. Spunt SL, Ashley Hill D, Motosue AM et al. Clinical features and outcome of initially unresected nonmetastatic pediatric nonrhaddomyosarcoma soft tissue sarcoma. J. Clin. Oncol. 20, 3225-3235 (2002).
7. Ferrari A, Casanova M. New concepts for the treatment of pediatric non-rhabdomyosarcoma soft tissue sarcomas. Expert Rev. Anticancer Ther. 5(2), 307-318 (2005).
8. Walter AW, Shearer PD, Pappo AS et al. A pilot study of vincristine, ifosfamide, and doxorubicin in the treatment of pediatric non-rhabdomyosarcoma soft tissue sarcomas. Med. Pediatr. Oncol. 30, 210-216 (1998).
9. Pratt CB, Maurer HM, Gieser P et al. Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: a Pediatric Oncology Group Study. Med. Pediatr. Oncol. 30, 201-209 (1998).
10. Pappo AS, Devidas M, Jenkins J et al. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosaroomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J. Clin. Oncol. 23, 4031-4038 (2005).
11. Nathan PC, Tsokos M, Long L et al. Adjuvant chemotherapy for the treatment of advanced pediatric nonrhabdomyosarcoma soft tissue sarcoma: the National Cancer Institute experience. Peidiatr. Blood Cancer 44, 449-454 (2005).
12. Edmonson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J. Clin. Oncol. 11, 1269-1275 (1993).
13. Antman K, Crowley J, Balcerzak SP et al. An intergroup Phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J. Clin. Oncol. 11, 1276-1285 (1993).
14. Patel SR, Vadhan-Raj S, Papadopolous N et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of Phase II and pilot studies - dose-response and schedule dependence. J. Clin. Oncol. 15, 2378-2384 (1997).
15. Rosen G, Forscher C, Lowenbraun S et al. Synovial sarcoma: uniform response of metastases to high dose ifosfamide. Cancer 73, 2506-2511 (1994).
16. Coindre JM, Terrier P, Guillou L et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 91, 1914-1926 (2001).
17. Trojani M, Contiesso G, Coindre JM et al. Soft tissue sarcomas of adults: study of pathological prognostic variables and definitions of a histopathological grading system. Int. J. Cancer. 33, 37-42 (1984).
18. Parham DM, Webber BL, Jenkins JJ et al. Nonrhabdomyosarcomatous soft tissue sarcomas of childhood: formulation of a simplified system for grading. Mod. Pathol. 8, 705-710 (1995).
19. Guillou L, Coindre JM, Bonichon F et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adults patients with soft tissue sarcoma. J. Clin. Oncol. 15, 350-362 (1997).
20. Ferrari A, Casanova M, Meazza C et al. Adult-type soft tissue sarcomas in pediatric age: experience at the Istituto Nazionale Tumori in Milan. J. Clin. Oncol. 23, 4021-4030 (2005).
21. DeLaney TF, Spiro IJ, Suit HD et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int. J. Radiat. Oncol. Biol. Phys. 56, 1117-1127 (2003).
22. O'Sullivan B, Davis AM, Turcotte R et al. Preoperative versus postoperative radiotherapy in soft tissue sarcoma of the limbs: a randomized trial. Lancet 359, 2235-2241 (2002)
23. Cormier JN, Langstein HN, Pisters PW. Preoperative therapy for soft tissue sarcoma. Cancer Treat. Res. 120, 43-63 (2004).
24. Wolfson AH. Preoperative vs postoperative radiation therapy for extremity soft tissue sarcoma: controversy and present management. Curr. Opin Oncol. 17(4), 357-360 (2005).
25. Rossi CR, Mocellin S, Pilati P et al. Hyperthermic isolated perfusion with low-dose tumor necrosis factor α and doxorubicin for the treatment of limb-threatening soft tissue sarcomas. Ann Surg Oncol. 12(5), 398-405 (2005).
26. Rossi CR, Deraco M, De Simone M et al. Hyperthermic intraperitoneal intratoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients. Cancer 100(9), 1943-1950 (2004).
27. Anderson PM, Pearson M. Novel therapeutic approaches in pediatric and young adult sarcomas. Curr. Oncol. Rep. 8(4), 310-315 (2006).
28. Bramwell V, Rouesse J, Steward W et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma - reduced local recurrence but no improvement in survival: a study on the European Organization for Research and Treatment of Cancer Soft Tissue Sarcoma and Bone Sarcoma Group. J. Clin. Oncol. 12, 1137-1149 (1994).
29. Bramwell VHC. Adjuvant chemotherapy for adult soft tissue sarcoma: is there a standard of care? J. Clin. Oncol. 19, 1235-1237 (2001).
30. Demetri G.D. Highlights of sarcoma research. J. Clin. Oncol. Classic Papers Curr. Comments 7, 681-684 (2002).
31. Alvegard TA, Sigurdsson H, Mouridsen H et al. Adjuvant chemotherapy with doxorubicin in high grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J. Clin. Oncol. 7, 1504-1513 (1989)
32. Santoro A, Tursz, T, Mouridsen H et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 13, 1537-1545 (1995).
33. No authors listed. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 350, 1647-1654 (1997).
34. Frustaci S, Gherlinzoni F, De Paoli A et al. Adjuvant chemotherapy for adult soft tissue sarcomas of extremities and girdles: results of the Italian randomized cooperative trial. J. Clin. Oncol. 19, 1238-1247 (2001).
35. Gronchi A, Olmi P, Casali PG. Combined modalities approach for localised adult extremity soft-tissue sarcoma. Expert Rev. Anticancer Ther. 7(8), 1135-1144 (2007).
36. Woll PJ, Van Glabbeke M, Hohenberger P et al. Adjuvant chemotherapy with doxorubicin and ifosfamide in resected soft tissue sarcoma: interim analysis of a Phase III trial. J. Clin. Oncol. 25(18 Suppl.), (2007) (Abstract 10008).
37. Cormier JN, Huang X, Xing Y et al. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J. Clin. Oncol. 22, 4567-4574 (2004).
38. Pratt CB, Pappo AS, Gieser P et al. Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J. Clin. Oncol. 17, 1219-1226 (1999)
39. Ferrari A, Brecht IB, Koscielniak E et al. The role of adjuvant chemotherapy in surgically-resected adult-type soft tissue sarcomas of children and adolescents. Pediatr. Blood Cancer 45, 128-134 (2005).
40. Ferrari A, Collini P. The effectiveness of chemotherapy in non-rhabdomyosarcoma soft tissue sarcomas. Pediatr. Blood Cancer 45(2), 226-227 (2005).
41. Ferrari A, Miceli R, Casanova M et al. Adult-type soft tissue sarcomas in pediatric age: a nomogram-based prognostic comparison with adult sarcomas. Eur. J. Cancer 43, 2691-2697 (2007).
42. Ladenstein R, Treuner J, Koscietniak E et al. Synovial sarcoma of childhood and adolescence: report of the German CWS-81 study. Cancer 71, 3647-3655 (1993).
43. Ferrari A, Casanova M, Massimino M et al. Synovial sarcoma: report of a series of 25 consecutive children from a single institution. Med. Pediatr. Oncol. 32, 32-37 (1999).
44. Pappo AS, Fontanesi J, Luo X et al. Synovial sarcoma in children and adolescents: the St. Jude Children's Research Hospital experience. J. Clin. Oncol. 12, 2360-2366 (1994).
45. Okcu MF, Munsell M, Treuner J et al. Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. J. Clin. Oncol. 21, 1602-1611 (2003).
46. Grobmyer SR, Maki RG, Demetri GD et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol. 15(11), 1667-1672 (2004).
47. Ferrari A, Gronchi A, Casanova M et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Caneer 101, 627-634 (2004).
48. Bergh P, Meis-Kindblom JM, Gherlinzoni F et al. Synovial sarcoma: identification oflow and high risk groups. Cancer 85, 2596-2607 (1999).
49. Lewis JJ, Antonescu CR, Leung DHY et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J. Clin. Oncol. 18, 2087-2094 (2000).
50. Spillane AJ, A'Hern R, Judson IR et al. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J. Clin. Oncol. 18, 3794-3803 (2000).
51. Trassard M, Le Doussal V, Hacène K et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J. Clin. Oncol. 19, 525-534 (2001).
52. Brecht IB, Ferrari A, Int-Veen C et al. Grossly-resected synovial sarcoma treated by the German and Italian pediatric soft tissue sarcoma cooperative group: discussion on the role of adjuvant therapies. Pediatr. Blood Cancer 46, 11-17 (2006).
53. Grier HE, Krailo MD, Tarbell NJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N. Engl. J. Med. 348(8), 694-701 (2003).
54. Raney RB, Asmar L, Newton WA Jr et al. Ewing's sarcoma of soft tissues in childhood: a report from the Intergroup Rhabdomyosarcoma Study 1972 to 1991. J. Clin. Oncol. 15(2), 574-582 (1997).
55. Castex MP, Rubie H, Stevens MC et al. Extraosseous localized ewing tumors: improved outcome with anthracyclines - the French society of pediatric oncology and international society of pediatric oncology. J. Clin. Oncol. 25(10), 1176-1182 (2007).
56. Kushner B H, La Quaglia M P, Wollner N et al. Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J. Clin. Oncol. 14, 1526-1531 (1996).
57. Brennan BMD, Foot ABM, Stiller C et al. Where to next with extracranial rhabdoid tumors in children. Eun J. Cancer 40, 624-626 (2004).
58. Loh ML, Ahn P, Perez-Atayde AR et al. Treatment of infantile fibrosarcoma with chemotherapy and surgery: results from the Dana-Farber Cancer Institute and Children's Hospital, Boston. Pediatr. Hematol. Oncol. 624, 722-726 (2002).
59. Bollinger BK, Laskin WB, Knight CB. Epithelioid hemangioendothelioma with multiple site involvement. Literature review and observations. Cancer 73, 610-615 (1994).
60. Fata F, O'Reilly E, Ilson D et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86, 2034-2037 (1999).
61. Penel N, Bui B, Bay JO et al. Weekly paclitaxel in metastatic angiosarocma. A FNCLCC French Sarcoma Group (GSF-GETO) Phase II trial. J. Clin. Oncol. 25(18 Suppl.), (2007) (Abstract 10002).
62. Hensley ML, Maki R, Venkatraman E et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a Phase II trial. J. Clin. Oncol. 20, 2824-2831 (2002).
63. Maki R, Hensley ML, Wathen JK et al. A SARC multicenter Phase III study of gemcitabine vs. gemcitabine and docetaxel in patients with metastatic soft tissue sarcoma. J. Clin. Oncol. 24(18 Suppl.), (2006) (Abstract 9514).
64. Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 8(7), 595-602 (2007).
65. Morgan JA, Le Cesne A, Chawla S et al. Randomized Phase II study of trabectidine in patients with liposarcoma and leiomysarcoma after failure of prior anthracycline and ifosfamide. J. Clin. Oncol. 25(18 Suppl.), (2007) (Abstract 10060).
66. Dileo P, Grosso F, Casanova M et al. Trabectidine in metastatic Ewing's family tumors patients progressing after standard chemotherapy. J. Clin. Oncol. 25(18 Suppl.), (2007) (Abstract 10040).
67. Casali PG, Messina A, Stacchiotti S et al. Imatinib mesylate in chordoma. Cancer 101(9), 2086-2097 (2004).
68. Heinrich MC, McArthur GA, Demetri GD et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J. Clin. Oncol. 24(7), 1195-203 (2006).
69. McArthur GA, Demetri GD, van Oosterom A et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J. Clin. Oncol. 23(4), 966-873 (2005).
70. D'Adamo DR, Keohan M, Schuetze S et al. Clinical results of a Phase II study of sorafenib in patients with non GIST sarcomas (CTEP study 7060). J. Clin. Oncol. 25(18 Suppl.), (2007) (Abstract 10001).
71. Chawla SP, Tolcher AW, Staddon AP et al. Survival results with AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue sarcomas: update of a Phase II trial. J. Clin. Oncol. 25(18 Suppl.), (2007) (Abstract 10076).